NCTX-1

N/A

Report date: 2026/05/21 20:00:22

Base Information

Drug NameNCTX-1

Drug Alias NameDual-CAR CD19/CD22 in vivo CAR-T therapy (NanoCell Therapeutics)NCTX-1

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy > In vivo CAR-T therapyCell and gene therapy > Cell therapy > In vivo cell therapy > In vivo CAR-T therapyBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Monoclonal antibody conjugate > Ab-tLNP

Mechanisms of ActionB-lymphocyte antigen CD19 modulatorsCD22 modulatorsT lymphocyte replacements

TargetsB-lymphocyte antigen CD19CD22

Therapy Area/IndicationsNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesNanoCell Therapeutics Inc

China Registration ClassN/A

Develop Information

Active CompaniesNanoCell Therapeutics Inc

Inactive CompaniesN/A

Active IndicationsNeoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A